EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

Articles

Exploring the science, practice, and people shaping the future of early developmental evaluation.

How to Talk to Families About the EarliPoint Evaluation

For providers using the EarliPoint System as part of the autism evaluation process, one of the recurring operational questions is how to […]

…

How ABA Practice Operations Are Evolving in 2026

The operational picture for ABA practices has shifted meaningfully over the last 18 to 24 months. Some of the change is driven […]

…

What Earns a Pediatrician’s Referral for Autism Evaluation

The autism diagnostic environment has matured, changing how pediatric practices think about referrals. Where once there were one or two specialty centers […]

…

Insurance Coverage for Autism Testing: What Parents Need to Know

Spotting the signs of autism is only the first step. Once a parent decides to pursue a formal evaluation, the next question […]

…

Screeners vs. Diagnostic Tools for Autism: What Do They Really Do?

If your child’s pediatrician hands you a questionnaire and says the results “raise some concerns,” what that really means is that your […]

…

Three Questions to Ask Before Adopting New Clinical Technology in Your Practice

The pace of clinical technology development in healthcare has accelerated. For practice owners and clinical directors evaluating new tools, the volume of […]

…
Request A Demo

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder